Switching to iGlarLixi vs continuation of glucagon-like peptide-1 receptor agonist in inadequately controlled type 2 diabetes: the randomised LixiLan-G trialL. Blonde,J. Rosenstock,S. Del Prato,R. Henry,N. Shehadeh,J. Frias,E. Niemoeller, E. Souhami,J. Wu, C. Ji, V. R. ArodaDIABETOLOGIA（2019）引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
